{"nctId":"NCT05393895","briefTitle":"An Evaluation of the Safety of CSF-1 in Presbyopic Subjects","startDateStruct":{"date":"2022-04-22","type":"ACTUAL"},"conditions":["Presbyopia"],"count":178,"armGroups":[{"label":"CSF-1","type":"EXPERIMENTAL","interventionNames":["Drug: CSF-1"]},{"label":"Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle"]}],"interventions":[{"name":"CSF-1","otherNames":["Qlosi"]},{"name":"Vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects must have presbyopia\n\nExclusion Criteria:\n\n* Have any contraindications to the study medications or diagnoses that would confound the study data","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment Emergent Adverse Events.","description":"As this is a safety study, no efficacy outcome has been defined.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":118},"commonTop":["Instillation site pain","Vision blurred","Conjuctival papillae","Conjunctival hyperaemia","COVID-19"]}}}